Smith Robert Paul JR 4

4 · Gossamer Bio, Inc. · Filed Mar 20, 2026

AI-generated summary of this filing

Updated Mar 20, 2026

Gossamer Bio CCO Robert P. Smith Receives Repriced Options

What Happened

Robert Paul Smith Jr., Chief Commercial Officer of Gossamer Bio (GOSS), had two sets of stock options cancelled and immediately regranted as part of a one-time option repricing. The transactions on 2026-03-19 show dispositions of 562,500 and 572,000 previously outstanding options and corresponding acquisitions/grants of the same amounts — a total of 1,134,500 options.
The repriced options now carry a reduced per-share exercise price of $0.45. The filing reports these as derivative transactions (options), not open-market stock sales or purchases, and no cash proceeds or share sales are reported.

Key Details

Transaction date: March 19, 2026. Effective as of the "Repricing Date" March 19, 2026 (Footnote F1).
Options cancelled and reissued: 562,500 and 572,000 (total 1,134,500) under the 2019 Incentive Award Plan.
New exercise price: $0.45 per share for the repriced options (Footnote F1).
Vesting/term: All other terms, including vesting and term, remain as previously set; grants vest per the original award agreements and require continued service (Footnote F2).
Shares/units owned after transaction: not specified in the reported data.
Filing timeliness: report covers activity on 2026-03-19 and was filed 2026-03-20; no late filing is indicated.

Context

This is a repricing (replacement of outstanding options) rather than a purchase or sale of common stock. It reduces the strike price of existing options, potentially making them more valuable if the stock rises above $0.45.
The repriced awards remain subject to their original vesting schedule and continued employment; this is not an immediate cashless exercise or sale of shares.

Form 4

Period: 2026-03-19

Chief Commercial Officer

Transactions

Disposition to Issuer
Stock Option (Right to Buy)
[F1][F2]
2026-03-19−562,500→ 0 total
Exercise: $2.88Exp: 2036-01-01→ Common Stock (562,500 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
[F1][F2]
2026-03-19−572,000→ 0 total
Exercise: $1.13Exp: 2035-03-03→ Common Stock (572,000 underlying)
Award
Stock Option (Right to Buy)
[F1][F2]
2026-03-19+562,500→ 562,500 total
Exercise: $0.45Exp: 2036-01-01→ Common Stock (562,500 underlying)
Award
Stock Option (Right to Buy)
[F1][F2]
2026-03-19+572,000→ 572,000 total
Exercise: $0.45Exp: 2035-03-03→ Common Stock (572,000 underlying)

Footnotes (2)

[F1]Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect.
[F2]This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

Signature

/s/ Jeff Boerneke, Attorney-in-Fact|2026-03-20

1 file